Analysis of randomly selected tumor types with high WBP2 amplification frequency of > 3% [TCGA liver hepatocellular (LIHC), ovarian cancer (OV) and uterine carcinosarcoma (UCS)] and low WBP2 amplification frequency of < 1% [TCGA colorectal cancer (COADREAD), acute myeloid leukemia (AML), uveal melanoma (UVM)] revealed varying correlation between WBP2 copy number and mRNA z‐scores (Fig. S1). This evidence concerns the gene WBP2 and neoplasm.